Nurix Therapeutics Inc

-0.48 (-1.46%)
Earnings Announcements

Nurix Therapeutics Reports Q2 Loss Per Share $0.60

Published: 07/13/2021 20:18 GMT
Nurix Therapeutics Inc (NRIX) - Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update.
Q2 Loss per Share $0.60.
Q2 Earnings per Share Estimate $-0.54 -- Refinitiv Ibes Data (analyst estimates).
On Track to Initiate Phase 1 Trials for Three Additional Wholly Owned Drug Candidates in 2021.
As of May 31, 2021, Nurix Had Cash, Cash Equivalents and Investments of $496.5 Million.
Revenue is expected to be $8.43 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $12.89 Million
Next Quarter EPS Guidance is expected to be -$0.59

More details on our Analysts Page.